124648-22-2

Upstream product

• 51548-88-0 (+/-)-1,2:4,5-di-O-isopropylidene-myo-inositol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 119874-35-0 1⁽³⁾-O-(tert-butyldiphenylsilyl)-2,3⁽¹⁾:5,6⁽⁴⁾-di-O-isopropylidene-D-myo-inositol 
• 119874-36-1 3-O-(tert-butyldiphenylsilyl)-6-O-camphanyl-1,2:4,5-di-O-isopropylidene-D-myo-inositol 

Downstream Products

• 119874-36-1 1-O-(tert-butyldiphenylsilyl)-4-O-camphanyl-2,3:5,6-di-O-isopropylidene-D-myo-inositol 
• 119874-36-1 3-O-(tert-butyldiphenylsilyl)-6-O-camphanyl-1,2:4,5-di-O-isopropylidene-D-myo-inositol 
• 119943-93-0 1-O-(tert-butyldiphenylsilyl)-2,3:5,6-di-O-isopropylidene-D-myo-inositol 
• 119874-40-7 2,3:5,6-di-O-isopropylidene-4-O-(4-methoxytetrahydropyran-4-yl)-D-myo-inositol 1-(2,3-di-O-hexadecanoyl-sn-glycer-1-yl phenyl phosphate) 
• 124649-44-1 6-O-(4-methoxytetrahydropyran-4-yl)-1,2:4,5-di-O-isopropylidene-D-myo-inositol 
• 119874-40-7 1,2:4,5-di-O-isopropylidene-6-O-(4-methoxytetrahydropyran-4-yl)-D-myo-inositol 3-(2,3-di-O-hexadecanoyl-sn-glycer-1-yl phenyl phosphate) 
• 119874-40-7 1,2:4,5-di-O-isopropylidene-6-O-(4-methoxytetrahydropyran-4-yl)-D-myo-inositol 3-(1,2-di-O-hexadecanoyl-sn-glycer-3-yl phenyl phosphate) 
• 119874-37-2 3-O-(tert-butyldiphenylsilyl)-6-O-(4-methoxytetrahydropyran-4-yl)-1,2:4,5-di-O-isopropylidene-D-myo-inositol 
• 119943-95-2 1D-myo-inositol-1-(1',2'-di-O-hexadecanoyl-sn-glycer-3'-yl sodium phosphate) 
• 119874-37-2 1-O-(tert-butyldiphenylsilyl)-4-O-(4-methoxytetrahydropyran-4-yl)-2,3:5,6-di-O-isopropylidene-D-myo-inositol 
• 119874-40-7 2,3:5,6-di-O-isopropylidene-4-O-(4-methoxytetrahydropyran-4-yl)-D-myo-inositol 1-(1,2-di-O-hexadecanoyl-sn-glycer-3-yl phenyl phosphate) 
• 161003-28-7 (3aR,4S,4aR,7aS,8S,8aR)-2,2,6,6-Tetramethyl-8-(tetrahydro-pyran-2-yloxy)-hexahydro-benzo[1,2-d;4,5-d']bis[1,3]dioxol-4-ol 
• 119874-38-3 4-O-(4-methoxytetrahydropyran-4-yl)-2,3:5,6-di-O-isopropylidene-D-myo-inositol 

Relevant academic research and scientific papers

Improved synthesis of myo-inositol 1-(4-nitrophenyl hydrogen phosphate), a chromogenic substrate for phosphatidylinositol-specific phospholipase C

This paper describes an improved procedure for the synthesis of racemic myo-inositol 1-(4-nitrophenyl hydrogen phosphate) (NPIP) a useful substrate for the continuous spectrophotometric assay of phosphatidylinositol-specific phospholipase C (PI-PLC).

Inhibition of human erythrocyte membrane phosphatidylinositol 4-kinase by phospholipid analogues

Analogues of phosphatidylinositol (PtdIns, 1) have been synthesized to investigate the structural requirements for inhibition of a PtdIns 4-kinase obtained from human erythrocyte membranes. While the presence of either D-1 or D-3 stereochemistry in the inositol moiety greatly influences the degree of inhibition produced by PtdIns analogues, the stereochemistry of the glycerol moiety is of little consequence. Neither structural feature however, makes a significant contribution to binding affinity. Competitive inhibitory activity was found to be retained (or even enhanced) in substantially simpler analogues consisting of 1 or 2 hydrocarbon chains attached to a charged phosphate head group, such as in the phosphatidic acids, 24 and 26. The observation that the phosphatidylinositol 4-phosphate (PtdIns 4P) and phosphatidic acid analogues (eg, 16 or 17, and 26 respectively) inhibit PtdIns 4-kinase may suggest that such species have a regulatory role in PtdIns turnover.

Total synthesis of the four stereoisomers of dihexadecanoyl phosphatidylinositol and the substrate stereospecificity of human erythrocyte membrane phosphatidylinositol 4-kinase

A new and convenient method for the preparation of the four stereoisomers of dihexadecanoyl phosphatidylinositol has been developed. An enantiomeric pair of acid-labile, pentaprotected myo-inositol building blocks was synthesized in high yield and coupled